MedTrace Logo

Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma

NCT00055640 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2010-06-10

No results posted yet for this study

Summary

RATIONALE: Analyzing genes that are present in cancer cells may be useful as a method for predicting the response of non-Hodgkin's lymphoma to cancer treatment. Imaging procedures such as positron emission tomography (PET) scans may improve the ability to measure how well cancer has responded to treatment.

PURPOSE: This phase II trial is studying molecular risk assessment to see how well it works in predicting response to therapy in patients who are receiving treatment for non-Hodgkin's lymphoma.

Conditions

Interventions

BIOLOGICAL

rituximab

Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.

DRUG

cyclophosphamide

Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.

DRUG

doxorubicin hydrochloride

Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.

DRUG

prednisone

Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.

DRUG

vincristine sulfate

Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.

GENETIC

microarray analysis

genetic testing

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Omer N. Koc, MD · Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2005-04-30
Completion
2006-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00055640 on ClinicalTrials.gov